Medication info
Pioformin Tablets 15/850 Milligrams

Pioformin Tablets 15/850 Milligrams

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Ilhwa Co., Ltd.
Appearance
White to grayish-white, rectangular film-coated tablet
Packaging
30 tablets (10 tablets/PTP * 3)
Approval status
Active

MFDS item code 201801687 · Approved 2018.04.20 · Insurance code 640903640

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
Ilhwa Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes to control their blood sugar more effectively. It is used as an adjunct to dietary and exercise therapy, containing pioglitazone and metformin which assist in blood glucose control. This stabilizes blood sugar levels and improves diabetes management.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with metformin or pioglitazone monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine once daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. No studies have been conducted to assess the safety and efficacy of switching from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the preceding 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication can cause severe lactic acidosis and hypoglycemia, so if such symptoms occur, you should immediately stop taking it and consult a doctor. Lactic acidosis is a rare but very serious condition, and the risk increases in cases of poor kidney function or conditions such as heart disease or infection. Patients with impaired liver function should avoid using this medication, and excessive alcohol consumption should also be avoided. In patients with heart failure, this medication may worsen symptoms, so any signs of heart failure should be reported to a doctor immediately. This medication should not be used in patients with severe renal impairment, active bladder cancer, or type 1 diabetes. Additionally, its administration should be temporarily suspended in cases of preoperative, postoperative, acute infections, or dehydration. While taking this medication, regular monitoring of blood glucose levels, kidney function, liver function, and hematological tests should be conducted, and particularly elderly patients should be more cautious. This medication may interact with other drugs, so if you are taking any other medications, you must inform your doctor or pharmacist. Pregnant or breastfeeding women should not take this medication, and premenopausal women should consider the possibility of pregnancy during the use of this medication and employ appropriate contraception. In case of overdose, you should immediately visit a medical institution for appropriate treatment, as some components may be removed by blood dialysis. While taking this medication, it is important to be attentive to any changes in symptoms, and if any adverse symptoms occur, immediate consultation with healthcare professionals is essential.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 33 more
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorder
  • worsening of diabetes
  • pharyngitis
  • anemia
  • vision reduction
  • diabetic macular edema
  • liver failure
  • congestive heart failure
  • edema
  • fractures
  • abnormal blood sugar levels
  • gastroenteritis
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intragastric air
  • increased serum creatinine
  • increased serum urea

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, ideally at room temperature between 1 to 30 degrees Celsius. This storage method will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

White to grayish-white, rectangular film-coated tablet

Package unit

30 tablets (10 tablets/PTP * 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.